CD80–CD28 costimulatory interaction (CD80-CD28)

The CD80–CD28 costimulatory interaction is a fundamental signaling axis in the adaptive immune system, providing the essential secondary signal required for full T-cell activation following antigen recognition by the T-cell receptor (TCR) (UniProt: P33681, P16284). CD80 (also known as B7-1), primarily expressed on professional antigen-presenting cells like dendritic cells and B cells, binds to the CD28 receptor on the surface of T-cells. This binding triggers intracellular signaling cascades, including the PI3K/Akt pathway, which promote T-cell survival, robust proliferation, and the secretion of critical cytokines such as interleukin-2 (StatPearls: T-Cell Activation). Without this costimulatory signal, T-cells that encounter their specific antigen may become anergic or undergo apoptosis, a mechanism vital for maintaining peripheral tolerance. In clinical medicine, this interaction is a major therapeutic target for modulating immune responses. Overactivity of the CD80–CD28 pathway is a hallmark of various autoimmune conditions and is the primary driver of acute rejection in organ transplantation. Drugs like abatacept and belatacept are fusion proteins consisting of the extracellular domain of CTLA-4 linked to an IgG1 Fc portion; they work by binding to CD80 (and the related CD86) with high affinity, thereby preventing CD28 engagement and effectively blocking T-cell activation (FDA Label: Orencia, Nulojix). Conversely, attempts to directly stimulate CD28 using superagonistic antibodies like TGN1412 resulted in catastrophic cytokine release syndrome in early clinical trials, highlighting the potent and potentially dangerous nature of this signaling pathway (NEJM: Suntharalingam et al., 2006). Current research continues to explore more selective CD28 antagonists and the role of this axis in enhancing anti-tumor immunity in oncology.

Other names

B7-1/CD28 pathwayCD80/CD28 axisB7-CD28 costimulationT-cell costimulatory signal 2B7-1:CD28 interaction

Costimulation blockade via competitive inhibition of CD28 binding to CD80/CD86, or direct agonism/antagonism of the CD28 receptor.